June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Analyzing the mitochondrial genome of over 2500 patients with retinal disease
Author Affiliations & Notes
  • Pernilla von Nandelstadh
    Blueprint Genetics, Espoo, Finland
  • Sari Tuupanen
    Blueprint Genetics, Espoo, Finland
  • Marta Gandia
    Blueprint Genetics, Espoo, Finland
  • Sanna Vattulainen-Collanus
    Blueprint Genetics, Espoo, Finland
  • Kati Kampjarvi
    Blueprint Genetics, Espoo, Finland
  • Johanna Kansakoski
    Blueprint Genetics, Espoo, Finland
  • Katja Merkkiniemi
    Blueprint Genetics, Espoo, Finland
  • Laura Sarantaus
    Blueprint Genetics, Espoo, Finland
  • Raquel Perez-Carro
    Blueprint Genetics, Espoo, Finland
  • Jonna Tallila
    Blueprint Genetics, Espoo, Finland
  • Ville Kytola
    Blueprint Genetics, Espoo, Finland
  • Mikko Muona
    Blueprint Genetics, Espoo, Finland
  • Johanna Sistonen
    Blueprint Genetics, Espoo, Finland
  • Inka Saarinen
    Blueprint Genetics, Espoo, Finland
  • Juha Koskenvuo
    Blueprint Genetics, Espoo, Finland
  • Tero-Pekka Alastalo
    Blueprint Genetics, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Pernilla von Nandelstadh, Blueprint Genetics (E); Sari Tuupanen, Blueprint Genetics (E); Marta Gandia, Blueprint Genetics (E); Sanna Vattulainen-Collanus, Blueprint Genetics (E); Kati Kampjarvi, Blueprint Genetics (E); Johanna Kansakoski, Blueprint Genetics (E); Katja Merkkiniemi, Blueprint Genetics (E); Laura Sarantaus, Blueprint Genetics (E); Raquel Perez-Carro, Blueprint Genetics (E); Jonna Tallila, Blueprint Genetics (E); Ville Kytola, Blueprint Genetics (E); Mikko Muona, Blueprint Genetics (E); Johanna Sistonen, Blueprint Genetics (E); Inka Saarinen, Blueprint Genetics (E); Juha Koskenvuo, Blueprint Genetics (E); Tero-Pekka Alastalo, Blueprint Genetics (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1531. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pernilla von Nandelstadh, Sari Tuupanen, Marta Gandia, Sanna Vattulainen-Collanus, Kati Kampjarvi, Johanna Kansakoski, Katja Merkkiniemi, Laura Sarantaus, Raquel Perez-Carro, Jonna Tallila, Ville Kytola, Mikko Muona, Johanna Sistonen, Inka Saarinen, Juha Koskenvuo, Tero-Pekka Alastalo; Analyzing the mitochondrial genome of over 2500 patients with retinal disease. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1531.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mitochondrial diseases are a heterogeneous group of disorders that arise as a result of dysfunction of the mitochondrial respiratory chain. The circular 16.5-kb mitochondrial genome (mtDNA) contains 37 genes, which are essential for normal mitochondrial function. Mitochondrial dysfunction caused by pathogenic/likely pathogenic variants in the mtDNA has been associated with retinal disease and vision loss. The goal of the study was to evaluate mtDNA variants in >2500 patients with inherited retinal disease (IRD).

Methods : We developed a highly sensitive and clinically validated mtDNA assay based on hybridization-based capture of mtDNA and next-generation sequencing (NGS) that is able to detect very low heteroplasmy levels of SNVs, INDELs and deletions. The mean read depth for the mtDNA was 18,224x, and 100% of base pairs were covered with a sequencing depth of at least 1000x. Sensitivity to detect SNVs and INDELs with over 10% heteroplasmy was 100%. For SNVs with 5-10% and <5% heteroplasmy levels the sensitivity was 93.3% and 88.9%, respectively. The mtDNA assay was included in diagnostic sequencing of 2597 IRD patients.

Results : A diagnostic (pathogenic/likely pathogenic) mtDNA variant was identified in 22 patients, contributing to a diagnostic yield of 0.85%. The 22 diagnostic variants included one heteroplasmic large deletion (7542bp) and 21 SNVs. Five of the SNVs were homoplasmic and 16 were heteroplasmic (>7%). Homoplasmic variants were associated mainly with Leber hereditary optic neuropathy (LHON). Diagnostic variants were identified in 8 mtDNA genes: MT-ND1, MT-ND4, MT-ND6, MT-ATP6, MT-TN, MT-TH, MT-TL1, and MT-TV. The most common variant was the retinal disease-associated MT-TL1 m.3243A>G, identified in 11 individuals in whom the retinal disease was most often described as macular/ cone dystrophy. Additionally, we reported a mtDNA VUS, likely to contribute to the patient’s diagnosis, in 7 cases.

Conclusions : Adding mtDNA analysis to routine genetic diagnostic process of IRD patients can increase the diagnostic yield by >0.85%. Analyzing the full mtDNA is beneficial as several different variants in mtDNA have been associated with both syndromic and non-syndromic IRD.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×